
TSHA Stock Forecast & Price Target
TSHA Analyst Ratings
Bulls say
Taysha Gene Therapies is a promising investment as evidenced by the company's strong pipeline, with its lead candidate TSHA-102 showing promising and differentiated efficacy data, a strong safety profile utilizing a well-validated delivery platform, and a potential for favorable reimbursement based on early results. Taysha's recent updates on clinical data and regulatory progress further support a positive outlook on the company's potential in the gene therapy space.
Bears say
Taysha Gene Therapies is operating in a highly competitive market, with several companies actively pursuing gene therapy treatments for CNS disorders like Rett Syndrome. Additionally, production issues can limit the supply of development candidates, and reimbursement for high-priced gene therapy treatments may be challenging. While the company's use of the well-established AAV9 mitigates some risks, increased penetration in each indication could lead to reduced revenues in the long term.
This aggregate rating is based on analysts' research of Taysha Gene Therapies and is not a guaranteed prediction by Public.com or investment advice.
TSHA Analyst Forecast & Price Prediction
Start investing in TSHA
Order type
Buy in
Order amount
Est. shares
0 shares